Featured image: A genomics laboratory illustrates cancer research. Contextual photograph; not a REGAIN site, an Alpha DaRT device or a participant in the brain-tumour study. Photo: National Cancer Institute / Unsplash. Unsplash licence.
Regulatory language can make an early experiment sound more advanced than it is. On 19 October 2026, Alpha Tau Medical announced that the US Food and Drug Administration had approved a supplement to its Investigational Device Exemption for the REGAIN brain-tumour study.
The decision allows the trial to expand from 10 to 20 participants and collect additional outcomes. It is not FDA marketing approval for Alpha DaRT, and the company’s SEC-filed announcement explicitly says the treatment has not been approved for commercial use in recurrent glioblastoma outside an authorised clinical trial.
Short-range alpha particles are placed inside the tumour
Alpha DaRT stands for Diffusing Alpha-emitters Radiation Therapy. The device uses small sources impregnated with radium-224. Placed inside a tumour, the sources release short-lived radioactive daughter atoms as the radium decays. Those daughters emit high-energy alpha particles over a short distance.
For the brain study, the company says neurosurgeons use stereotactic guidance—a three-dimensional navigation method—to insert sources through a burr hole rather than an open craniotomy. The intended advantage is concentrated radiation near the tumour while limiting exposure to surrounding tissue.
“Intended” is the right word at this stage. Physical range is only one part of clinical performance. Placement, diffusion, tumour geometry, radiation dose, neurological effects and later complications all require study in people.
REGAIN is designed first for feasibility and safety
The REGAIN registry entry, NCT06910306 describes a prospective, interventional, open-label, single-arm, multicentre study. Prospective means outcomes are followed forward from enrolment. Open-label means treatment is known. Single-arm means there is no randomly assigned control group receiving another intervention.
The study enrols people with recurrent glioblastoma, or now certain IDH-mutant grade 4 tumours, that cannot be surgically removed and have already received radiation to the central nervous system. Its principal purpose is to assess whether the procedure can be delivered and what safety events occur.
The amended protocol adds progression-free survival as a secondary endpoint, introduces regular quality-of-life assessments and provides another interim analysis six months after the fifth participant’s July 2026 treatment. Those additions improve the questions the trial can ask. They do not turn a 20-person single-arm study into a comparative efficacy trial.
Doubling enrolment still leaves a small denominator
An increase from 10 to 20 participants is a 100% expansion, but the absolute number remains small. In rare or difficult early-stage device studies, a small cohort can be appropriate for identifying procedural problems and obvious safety signals. It is much less able to estimate uncommon harms or separate treatment effects from differences among participants.
Recurrent brain tumours also create difficult imaging questions. Treatment-related inflammation can resemble tumour growth, a phenomenon called pseudoprogression. That is why REGAIN lists radiographic local control and pseudoprogression among its secondary measures rather than treating every scan change as a straightforward response.
Alpha Tau previously reported interim observations from the first three treated participants. Three is too small a group for a reliable response rate or survival conclusion. The next presentation may be informative, but conference data and company releases still require careful attention to denominators, follow-up and independent review.
The FDA decision regulates investigation, not effectiveness claims
An Investigational Device Exemption permits a device that is not commercially approved to be studied under specified conditions. Approving a supplement means the regulator has allowed the proposed protocol change. It does not mean the FDA has concluded that the device is effective or ready for routine care.
The next useful evidence will be concrete: how many participants received all planned sources, what procedure-related and radiation-related events occurred, how quality of life changed, and how long imaging and survival outcomes were followed. Later studies would need to address comparison with available care and which patients, if any, benefit.
REGAIN’s expansion matters because it creates room for a broader safety and feasibility dataset in an area with severe unmet need. The responsible headline is also the accurate one: the study has permission to learn more. The treatment has not yet earned a commercial or clinical-effectiveness conclusion.
Reporting and source checks completed on 21 October 2026. By FutureTechDose Editor.
Leave a Reply